The aim of our institute is to deepen the understanding of mechanisms that promote or prevent the onset of metabolic diseases with focus on type 2 diabetes and fatty liver disease. We investigate the beneficial preventive effect of exercise on a molecular level and study the compensatory mechanisms in mitochondria, as well as the role of other subcellular structures. To this end, we apply multi-OMICs approaches combined with functional assays. Another focus is on genetic variants and mechanisms that impact the progression of fatty liver disease. It is also our goal to identify biomarkers that can identify risk phenotypes predict the development and progression of metabolic diseases.
Another goal of our institute, focusing on clinical chemical and analytical research, is to develop and validate OMICs and other analytical methods and novel sample pre-treatment strategies. Moreover, we establish biomarkers to control the pre-analytical phase and quality of clinical samples.